Opinion

Video

Timeline of Enfortumab Vedotin in UC: From Previously Treated UC to Frontline Therapy

Author(s):

Thomas Powles MBBS, MRCP, MD

Thomas Powles, MBBS, MRCP, MD, discusses how antibody-drug conjugates have demonstrated improvement over chemotherapy. Data from the EV-301 trial shows that the antibody-drug conjugate enfortumab vedotin decreased the risk of death by 30% versus chemotherapy. Later trial data showed that treatment using enfortumab vedotin plus pembrolizumab (EV+P) reduced the risk of patient death by 53%.

Related Videos
John K. Lee, MD, PhD, associate professor-in-residence, Division of Hematology/Oncology, Department of Medicine; the Institute for Urologic Oncology, Department of Urology, the David Geffen School of Medicine, UCLA Heath
5 experts are featured in this series
4 experts are featured in this series.
Related Content
Urothelial Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 15th 2025

FDA Approval Is Sought for TAR-200 in BCG-Unresponsive High-Risk NMIBC With CIS

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Cancer | Image Credit: © Cornflakesei - stock.adobe.com
January 10th 2025

Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Urothelial Cancer | stock.adobe.com
January 3rd 2025

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

Urothelial Carcinoma | Image Credit: © Sebastian Kaulitzki- stock.adobe.com
December 19th 2024

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma